Comparative Pharmacology
Head-to-head clinical analysis: CRYSELLE versus MICROGESTIN 1 5 30.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CRYSELLE versus MICROGESTIN 1 5 30.
CRYSELLE vs MICROGESTIN 1.5/30
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cryselle is a combination oral contraceptive containing ethinyl estradiol and norgestrel. It inhibits ovulation by suppressing gonadotropin release, primarily through estrogenic and progestogenic effects on the hypothalamic-pituitary axis. It also increases cervical mucus viscosity and alters endometrial structure, impeding sperm penetration and implantation.
Combination oral contraceptive containing norethindrone acetate (progestin) and ethinyl estradiol (estrogen). Suppresses gonadotropin secretion (FSH, LH) via negative feedback on hypothalamic-pituitary axis, preventing ovulation. Also increases cervical mucus viscosity and alters endometrial receptivity.
One tablet (0.3 mg norgestrel/0.03 mg ethinyl estradiol) orally once daily at the same time each day for 21 consecutive days, followed by 7 days of placebo.
One tablet (norethindrone acetate 1.5 mg/ethinyl estradiol 30 mcg) orally once daily at the same time each day for 21 consecutive days, followed by 7 days of placebo tablets.
None Documented
None Documented
Terminal elimination half-life approximately 24 hours (range 16-36 h), with clinical significance for once-daily dosing.
Norethindrone: 8-11 hours; Ethinyl estradiol: 13-19 hours. Steady-state reached within 5-7 days.
Renal (50% as metabolites, 20% unchanged), fecal (30%), with enterohepatic recirculation.
Renal: ~50-60% (primarily as glucuronide conjugates of ethinyl estradiol and norethindrone); Fecal: ~40-50% (via biliary elimination)
Category C
Category C
Oral Contraceptive
Oral Contraceptive